Targeted Genetics acquires Genovo and strikes Biogen deal

TGEN will acquire gene therapy company Genovo (Sharon Hill, Penn.) for 6.63 million shares of TGEN stock, valuing the deal at $67 million. Genovo is developing adeno-associated viral (AAV) vector gene therapies to treat hyperlipidemia, atherosclerosis and hemophilia, and associated intellectual property covering AAV and other viral vectors. Genovo also has a collaboration with Genzyme covering the development of viral based products to treat lysosomal storage disorders. ...